(S)-(+)-2-methyl-2-(4-methoxyphenyl)glycine | 170688-63-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-(+)-2-methyl-2-(4-methoxyphenyl)glycine
• 英文别名: (S)-(-)-α-4-methoxyphenylalanine；(S)-α-Amino-4-methoxy-α-methylbenzeneacetic Acid；(2S)-2-azaniumyl-2-(4-methoxyphenyl)propanoate
• CAS: 170688-63-8
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: CAILUIWIXZDVSZ-JTQLQIEISA-N

物化性质

• 熔点：
  256-257 °C
• 沸点：
  345.3±37.0 °C(Predicted)
• 密度：
  1.205±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-(+)-2-methyl-2-(4-methoxyphenyl)glycine 在 palladium on activated charcoal 盐酸 、 氟化铵 、 lithium hydroxide 、 N-羟基-7-氮杂苯并三氮唑 、 氢气 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二乙二醇二甲醚 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(methanesulfonamido)phenyl]ethyl]amino]-N-(2-methoxyphenyl)-2-(4-methoxyphenyl)propanamide
  参考文献：
  名称：

  BMS-201620: a selective beta 3 agonist

  摘要：

  A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human beta(3) adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent beta(3) full agonist (K-i = 93 nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.074
• 作为产物：
  描述：

  (2S)-(+)-[(S)-N-p-toluenesulfinyl]-2-amino-2-(4-methoxyphenyl)propionitrile 在 盐酸 作用下， 反应 15.0h， 以54%的产率得到(S)-(+)-2-methyl-2-(4-methoxyphenyl)glycine
  参考文献：
  名称：

  亚磺胺介导的不对称strecker合成在α-烷基α-氨基酸合成中的应用。

  摘要：

  将Et（2）AlCN和i-PrOH加至酮亚磺胺（N-亚磺酰基亚胺）可以中等至良好的产率获得相应的α-烷基α-氨基腈。非对映选择性在很大程度上取决于酮亚磺胺的E / Z异构体比率。非对映体纯氨基腈的水解以中等至良好的产率提供对映体纯的α-烷基α-氨基酸。

  DOI：

  10.1021/jo001179z

文献信息

• Efficient Biocatalytic Synthesis of Highly Enantiopureα-Alkylated Arylglycines and Amides
  作者：Mei-Xiang Wang、Shuan-Jun Lin、Jun Liu、Qi-Yu Zheng

  DOI：10.1002/adsc.200303219

  日期：2004.3

  racemic α-alkylarylglycine amides including 1-amino-1-carbamoyl-1,2,3,4-tetrahydronaphthalene underwent efficient biocatalytic hydrolysis under very mild conditions to afford the corresponding (S)-α-alkylarylglycines and (R)-α-alkylarylglycine amides in excellent yields with enantiomeric excesses higher than 99.5%. Both the reaction rate and enantioselectivity of biocatalytic kinetic resolution were strongly

  包括1-氨基-1-氨基甲酰基-1,2,3,4-四氢萘在内的许多外消旋α-烷基芳基甘氨酸酰胺在非常温和的条件下进行了有效的生物催化水解，得到相应的（S）-α-烷基芳基甘氨酸和（R）- α-烷基芳基甘氨酸酰胺具有优异的收率，对映体过量高于99.5％。生物催化动力学拆分的反应速率和对映选择性都强烈取决于取代基的性质和底物苯环上的取代方式。相反，在含腈水化酶/酰胺酶的微生物红球菌的催化下，未观察到源自苯乙酮的Strecker腈的有效生物转化。sp。AJ270全细胞催化剂。结合酰胺的化学水解，该生物转化过程从容易获得的外消旋酰胺提供了两种对映体形式的α-取代的芳基甘氨酸的有效合成。
• Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such
  申请人：Nique Francois

  公开号：US20100063120A1

  公开（公告）日：2010-03-11

  Compounds of formula (I): wherein X is O or S, R 1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R 2 is H. alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R 3 and R 4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R 3 and R 4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R 5 is H, halogen, trifluoromethyl, —CN, or —NO2; not all of R 3 , R 4 , and R 5 being H, R 6 and R 9 are H, halogen, OH; alkyl. hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R 7 and R 8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R 7 and R 8 not being H or halogen; or one of R 7 and R 8 is a pharmaceutically acceptable ester or thioester grouping, or R 6 is C 1-3 -alkyl or, together with either R 1 or R 2 , represents C 1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

  式(I)的化合物：其中X为O或S，R1为酰基，醛基，环烷基，或可选择地取代的烷基，烯基或炔基，R2为H，烷基，羟基烷基，卤代烷基，烯基或炔基；取代烷基；烷基羰基；R3和R4为H，卤素，烷基，烯基，炔基，烷氧基，烷硫基，羟基烷基，卤代烷基，卤代烯基，或卤代炔基；或R3和R4形成一个，可选择的芳香或杂环，可选择地取代的环，R5为H，卤素，三氟甲基，-CN，或-NO2；R3，R4和R5中不全为H，R6和R9为H，卤素，羟基；烷基，羟基烷基，烷氧基，硫代烷基，卤代烷基，烯基，或炔基；R7和R8为H，卤素，羟基，硫氢基；烷氧基或烷硫基，可选择地由羟基和/或卤素取代；R7和R8中的一个不为H或卤素；或R7和R8中的一个为药用可接受的酯或硫酯基团，或R6为C1-3-烷基或，与R1或R2中的任一者一起，代表C1-3烷基或烯基链连接基，可选择地由甲基，三氟甲基，羟基，或卤素取代，以及其药用可接受的盐和酯，可用作选择性雄激素调节剂。
• IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH
  申请人：NIQUE Francois

  公开号：US20100210699A1

  公开（公告）日：2010-08-19

  Compounds of formula (I): wherein X is O or S, R 1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R 2 is H, alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R 3 and R 4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R 3 and R 4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R 5 is H, halogen, trifluoromethyl, —CN, or —NO 2 ; not all of R 3 , R 4 , and R 5 being H, R 6 and R 9 are H, halogen, OH; alkyl, hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R 7 and R 8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R 7 and R 8 not being H or halogen; or one of R 7 and R 8 is a pharmaceutically acceptable ester or thioester grouping, or R 6 is C 1-3 -alkyl or, together with either R 1 or R 2 , represents C 1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

  化合物式（I）：其中X为O或S，R1为酰基，醛基，环烷基，可选取代的烷基，烯基或炔基，R2为H，烷基，羟基烷基，卤代烷基，烯基或炔基；取代烷基；烷基羰基；R3和R4为H，卤素，烷基，烯基，炔基，烷氧基，烷硫基，羟基烷基，卤代烷基，卤代烯基或卤代炔基；或R3和R4形成一个可选的芳香或杂环，可选取代的环，R5为H，卤素，三氟甲基，—CN或—NO2；R3，R4和R5不全为H，R6和R9为H，卤素，OH；烷基，羟基烷基，烷氧基，硫代烷基，卤代烷基，烯基或炔基；R7和R8为H，卤素，OH，SH；烷氧基或烷硫基，可选取代为OH和/或卤素；R7和R8中的一个不为H或卤素；或R7和R8中的一个是药物可接受的酯或硫酯基团，或R6为C1-3烷基或与R1或R2中的一个共同表示C1-3烷基或烯基链连接基团，可选取代为甲基，三氟甲基，OH或卤素，以及其药物可接受的盐和酯，用作选择性雄激素调节剂。
• Discovery of Diarylhydantoins as New Selective Androgen Receptor Modulators
  作者：François Nique、Séverine Hebbe、Christophe Peixoto、Denis Annoot、Jean-Michel Lefrançois、Eric Duval、Laurence Michoux、Nicolas Triballeau、Jean-Michel Lemoullec、Patrick Mollat、Maxime Thauvin、Thierry Prangé、Dominique Minet、Philippe Clément-Lacroix、Catherine Robin-Jagerschmidt、Damien Fleury、Denis Guédin、Pierre Deprez

  DOI：10.1021/jm300249m

  日期：2012.10.11

  A novel selective androgen receptor modulator scaffold has been discovered through structural modifications of hydantoin antiandrogens. Several 4-(4-hydroxyphenyl)-N-arylhydantoins displayed partial agonism with nanomolar in vitro potency in transactivation experiments using androgen receptor (AR) transfected cells. In a standard castrated male rat model, several compounds showed good anabolic activity on levator ani muscle, dissociated from the androgenic activity on ventral prostate, after oral dosing at 30 mg/kg. (+)-4-[3,4-Dimethyl-2,5-dioxo-4-(4-hydroxyphenyl)imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile ((+)-11b) displayed anabolic potency with a strong dissociation between levator ani muscle and ventral prostate (A(50) = 0.5 mg/kg vs 70 mg/kg). The binding modes of two compounds, including (+)-11b, within the AR ligand-binding domain have been studied by cocrystallization experiments using a coactivator-like peptide. Both compounds bound to the same site, and the overall structures of the AR were very similar.
• US5770615A
  申请人：——

  公开号：US5770615A

  公开（公告）日：1998-06-23